Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has big plans for the combo therapy.
Randy Osborne is a staff writer for BioWorld Today, a publication focused on the biotechnology industry. With a talent for storytelling and a knack for creating new things, Randy's articles cover a wide range of topics within the biotech field, including company developments, clinical trials, and industry trends.